Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contraloid acetate in MCI due to Alzheimer's Disease
NCT04711486Phase 1Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Contraloid acetate with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Related Adverse Events, Number of Participants with abnormal laboratory values and 1 more. Started Dec 2020; status: completed.
02
Drugs
PRI-002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04711486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711486.